In 2012, the number of people infected with human T cell lymphotropic virus type 1 (HTLV-1) was estimated to be 10 million worldwide. Prevalence varies according to geographic location, ethnic factors, sex, age, populations exposed to risk factors, income, and education, reaching countries with the worst socioeconomic scenarios. There is a need to determine the current global prevalence of HTLV-1 and examine its association with countries' human development index (HDI) to provide data for global health policy. Systematic review with meta-analysis is according to PRISMA 2020 recommendations. It was registered at PROSPERO, CRD42021223146. Prevalence or cross-sectional studies of HTLV-1 infection with at least 100 participants, screening, and confirmatory serologic testing were included. Studies with incomplete or unavailable results or with duplicate information were excluded. Data were selected by two independent investigators and analyzed using R software, a metapackage that generated the forest plots [95% confidence interval (CI)]. Heterogeneity was assessed using the I2 statistic, and funnel plot asymmetry was assessed using Egger's test. Countries were compared using an HDI cutoff ≥0.8. Methodological quality was assessed using Joanna Briggs Institute (JBI) criteria. The overall prevalence of HTLV-1 infection was 0.91% (95% CI: 0.80–1.02, p < .0001) and was higher in low HDI countries [1.18% (95% CI: 1.03–1.34)] than in high HDI countries [0.41% (95% CI: 0.27–0.57)]. Prevalence varied according to the populations studied: it was higher in the general population [1.65% (95% CI: 1.08–2.34)] compared to pregnant women [0.34% (95% CI: 0.17–0.57)] and blood donors [0.04% (95% CI: 0.01–0.08)]. Consistently, prevalence for each population group was higher in low HDI countries than in high HDI countries. The worldwide prevalence of HTLV-1 infection is highly heterogeneous, with a global prevalence of 0.91%. In high HDI countries, the observed prevalence is approximately three times lower than in low HDI countries. In the general population, the observed prevalence is about 5 times higher than in pregnant women and 41 times higher than in blood donors.
Get full access to this article
View all access options for this article.
References
1.
Catalan-SoaresBC, ProiettiFA, de Freitas Carneiro-ProiettiAB. Os vírus linfotrópicos de células T humanos (HTLV) na última década (1990-2000): Aspectos epidemiológicos [Internet]. Rev Brasil Epidemiol, 2001; 4:81–95; doi: 10.1590/s1415-790x2001000200003
2.
PoieszBJ, RuscettiFW, GazdarAF, et al.Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A, 1980; 77(12):7415–7419.
3.
GalloRC.The discovery of the first human retrovirus: HTLV-1 and HTLV-2 [Internet]. Retrovirology, 2005; 2:17; doi:10.1186/1742-4690-2-17
4.
RomanelliLCF, CaramelliP, Proietti AB deFC. [Human T cell lymphotropic virus (HTLV-1): When to suspect infection?]. Rev Assoc Med Bras, 2010; 56(3):340–347.
5.
BittencourtAL.Adult T-cell leukemia/lymphoma (ATL) in Bahia, Brazil [Internet]. Br J Infect Dis, 2005; 9:437–438; doi: 10.1590/s1413-86702005000500020
6.
OsameY, ToyodaK, TsumuraY, et al.Sludge deposition in molten aluminum die casting alloys in the holding furnace [Internet]. J Japan Inst Light Metals, 1986; 36:813–818; doi: 10.2464/jilm.36.813
LaGrenadeL, HanchardB, FletcherV, et al.Infective dermatitis of Jamaican children: A marker for HTLV-I infection. Lancet, 1990; 336(8727):1345–1347.
9.
VerdonckK, GonzálezE, Van DoorenS, et al.Human T-lymphotropic virus 1: Recent knowledge about an ancient infection. Lancet Infect Dis, 2007; 7(4):266–281.
10.
AraújoMG, GonçalvesDU, Carneiro-ProiettiABF, et al.Cutaneous manifestations in human T-cell lymphotropic virus type 1 infection [Internet]. Anais Brasil Dermatol, 2008; 83:393–407; doi: 10.1590/s0365-05962008000500002
11.
DouradoI, AlcantaraLCJ, BarretoML, et al.HTLV-I in the general population of Salvador, Brazil: A city with African ethnic and sociodemographic characteristics. J Acquir Immune Defic Syndr, 2003; 34(5):527–531.
12.
GessainA, CassarO. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol, 2012; 3:388.
13.
EtennaSL-D, CaronM, BessonG, et al.New insights into prevalence, genetic diversity, and proviral load of human T-cell leukemia virus types 1 and 2 in pregnant women in Gabon in equatorial central Africa. J Clin Microbiol, 2008; 46(11):3607–3614.
14.
Carneiro-ProiettiABF, RibasJGR, Catalan-SoaresBC, et al.Infection and disease caused by the human T cell lymphotropic viruses type I and II in Brazil [Internet]. Rev Soc Brasil Med Trop, 2002; 35:499–508; doi: 10.1590/s0037-86822002000500013
15.
SilvaOMP da, da SilvaOMP, PanhocaL. The contribution of vulnerability to determining the human development index: studying Santa Catarina State, Brazil [Internet]. Ciên Saúde Colet, 2007; 12:1209–1219; doi: 10.1590/s1413-81232007000500018
16.
IDH [Internet]. [2021 May 23]. Available from: https://www.br.undp.org/content/brazil/pt/home/idh0.html
17.
Barros MB deA, de Azevedo BarrosMB. A importância dos sistemas de informação e dos inquéritos de base populacional para avaliações de saúde [Internet]. Epidemiol Serv Saúde, 2004; 13; doi: 10.5123/s1679-49742004000400001
18.
HlelaC, ShepperdS, KhumaloNP, et al.The prevalence of human T-cell lymphotropic virus type 1 in the general population is unknown. AIDS Rev, 2009; 11(4):205–214.
19.
Catalan-SoaresB, Carneiro-Proietti AB deF, ProiettiFA, et al.Heterogeneous geographic distribution of human T-cell lymphotropic viruses I and II (HTLV-I/II): Serological screening prevalence rates in blood donors from large urban areas in Brazil. Cad Saude Publ, 2005; 21(3):926–931.
20.
PageMJ, McKenzieJE, BossuytPM, et al.The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 2021; 372: n71.
21.
OuzzaniM, HammadyH, FedorowiczZ, et al.Rayyan-a web and mobile app for systematic reviews. Syst Rev, 2016; 5(1):210.
22.
MunnZ, MoolaS, LisyK, et al.Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data [Internet]. Int J Evid-Based Healthcare, 2015; 13:147–153; doi: 10.1097/xeb.0000000000000054
23.
SantosWM dos, SecoliSR, Püschel VA deA.The Joanna Briggs Institute approach for systematic reviews. Rev Latino-Am Enfermagem [Internet] 2018 Nov 14 [cited 2021 Oct 31];26. Available from: https://www.scielo.br/j/rlae/a/3X4PW3B8fzcrpH6YvgZhCJH/?lang=en&format=pdf
24.
Website [Internet]. Available from: https://hdr.undp.org/en/content/human-development-report-2020-readers-guide
25.
Reis MC deS. Metanálise e síntese de evidências na área da saúde: Um estudo da prevalência de diabetes no Brasil; 2013 Dec 3 [cited 2021 Nov 29]. Available from: http://bdm.unb.br/handle/10483/8315
26.
ViechtbauerW.Conducting meta-analyses in R with the meta for package [Internet]. J Stat Softw, 2010; 36; doi: 10.18637/jss.v036.i03
27.
PereiraMG, GalvãoTF. Heterogeneidade e viés de publicação em revisões sistemáticas [Internet]. Epidemiol Serv Saúde, 2014; 23:775–778; doi: 10.5123/s1679-49742014000400021
28.
HigginsJPT, ThompsonSG. Quantifying heterogeneity in a meta-analysis. Stat Med, 2002; 21(11):1539–1558.
29.
EggerM, Davey SmithG, SchneiderM, et al.Bias in meta-analysis detected by a simple, graphical test. BMJ, 1997; 315(7109):629–634.
30.
BouzasMB, ZapiolaI, QuiruelasS, et al.HTLV type I and HTLV type II infection among Indians and natives from Argentina. AIDS Res Hum Retroviruses, 1994; 10(11):1567–1571.
31.
BrunRO, AstarloaL, SalomonHE, et al.[Prevalence of HTLV-I/II infection among blood donors in Santa Fe Province, Argentina]. Medicina, 2004; 64(2):125–128.
32.
BiglioneMM, AstarloaL, SalomónHE, et al.High prevalence of HTLV-I and HTLV-II among blood donors in Argentina: A South American health concern. AIDS Res Hum Retroviruses, 2005; 21(1):1–4.
33.
BeriniCA, PandoMA, BautistaCT, et al.HTLV-1/2 among high-risk groups in Argentina: Molecular diagnosis and prevalence of different sexual transmitted infections. J Med Virol, 2007; 79(12):1914–1920.
34.
BeriniCA, DelfinoC, TorresO, et al.HTLV-1 cosmopolitan and HTLV-2 subtype b among pregnant women of non-endemic areas of Argentina. Sex Transm Infect, 2013; 89(4):333–335.
35.
EinsiedelL, PhamH, TalukderMR, et al.Very high prevalence of infection with the human T cell leukaemia virus type 1c in remote Australian Aboriginal communities: Results of a large cross-sectional community survey. PLoS Negl Trop Dis, 2021; 15(12):e0009915.
36.
DumasM, HouinatoD, VerdierM, et al.Seroepidemiology of human T-cell lymphotropic virus type I/II in Benin (West Africa). AIDS Res Hum Retroviruses, 1991; 7(5):447–451.
37.
de AraujoAC, de AraujoAC, do Rosario CassebJS, et al.HTLV-I and HTLV-II infections among HIV-1 seropositive patients in Sao Paulo, Brazil [Internet]. Eur J Epidemiol, 1994; 10:165–171; doi: 10.1007/bf01730366
38.
BroutetN, de Queiroz SousaA, Placido BasilioF, et al.Prevalence of HIV-1, HIV-2 and HTLV antibody, in Fortaleza, Ceara, Brazil, 1993-1994 [Internet]. Int J STD AIDS, 1996; 7:365–369; doi: 10.1258/0956462961918103
39.
BrittoAPCR, BrittoAPC, Galvão-CastroB, et al.Infecção pelo HTLV-I/II no Estado da Bahia [Internet]. Rev Soc Brasil Med Trop, 1998; 31:35–41; doi: 10.1590/s0037-86821998000100005
40.
VallinotoACR, PontesGS, MutoNA, et al.Identification of human T-cell lymphotropic virus infection in a semi-isolated Afro-Brazilian quilombo located in the Marajó Island (Pará, Brazil) [Internet]. Mem Inst Oswaldo Cruz, 2006; 101:103–105; doi: 10.1590/s0074-02762006000100020
41.
de Lourdes BastosM, OsterbauerB, MesquitaDL, et al.Prevalence of human T-cell lymphotropic virus type 1 infection in hospitalized patients with tuberculosis. Int J Tuberc Lung Dis, 2009; 13(12):1519–1523.
42.
NascimentoLB do, do NascimentoLB, dos Santos CarneiroMA, et al.Prevalência da infecção pelo HTLV-1, em remanescentes de quilombos no Brasil Central [Internet]. Rev Soc Brasil Med Trop, 2009; 42:657–660; doi: 10.1590/s0037-86822009000600009
43.
SequeiraCG, Tamegão-LopesBP, dos SantosEJM, et al.Descriptive study of HTLV infection in a population of pregnant women from the State of Pará, Northern Brazil [Internet]. Rev Soci Brasil Med Trop, 2012; 45:453–456; doi: 10.1590/s0037-86822012005000007
44.
Guimarães de SouzaV, Lobato MartinsM, Carneiro-Proietti AB deF, et al.High prevalence of HTLV-1 and 2 viruses in pregnant women in São Luis, state of Maranhão, Brazil. Rev Soc Bras Med Trop, 2012; 45(2):159–162.
45.
MelloMAG, da ConceiçãoAF, SousaSMB, et al.HTLV-1 in pregnant women from the Southern Bahia, Brazil: A neglected condition despite the high prevalence. Virol J, 2014; 11:28.
46.
BandeiraLM, UeharaSNO, AsatoMA, et al.High prevalence of HTLV-1 infection among Japanese immigrants in non-endemic area of Brazil. PLoS Negl Trop Dis, 2015; 9(4):e0003691.
47.
Caterino-de-AraujoA, SacchiCT, GonçalvesMG, et al.Short communication: Current prevalence and risk factors associated with human T lymphotropic virus type 1 and human T lymphotropic virus type 2 infections among HIV/AIDS patients in São Paulo, Brazil. AIDS Res Hum Retroviruses, 2015; 31(5):543–549.
48.
NunesD, Boa-SorteN, GrassiMFR, et al.HTLV-1 is predominantly sexually transmitted in Salvador, the city with the highest HTLV-1 prevalence in Brazil. PLoS One, 2017; 12(2):e0171303.
49.
CastroLS, RezendeGR de, FernandesFRP, et al.Human T cell lymphotropic virus type 1 infection among men who have sex with men in Central Brazil. Braz J Infect Dis, 2018; 22(6):472–476.
50.
SilvaIC, PinheiroBT, NobreAFS, et al.Moderate endemicity of the human T-lymphotropic virus infection in the metropolitan region of Belém, Pará, Brazil [Internet]. Rev Brasil Epidemiol, 2018; 21; doi: 10.1590/1980-549720180018
51.
MarconCEM, CamposKR, da SilvaGB, et al.The first survey of human T-cell lymphotropic viruses (HTLV) in HIV/AIDS patients in Santa Catarina State, Brazil [Internet]. Rev Inst Med Trop São Paulo, 2019; 61; doi: 10.1590/s1678-9946201961053
52.
Oliveira-FilhoAB, AraújoAPS, SouzaAPC, et al.Human T-lymphotropic virus 1 and 2 among people who used illicit drugs in the State of Pará, Northern Brazil. Sci Rep, 2019; 9(1):14750.
53.
PereiraFM, de Almeida M daCC, SantosFLN, et al.Evidence of new endemic clusters of human T-cell leukemia virus (HTLV) infection in Bahia, Brazil. Front Microbiol, 2019; 10:1002.
54.
AlencarSP, Souza M deC, Fonseca RR deS, et al.Prevalence and molecular epidemiology of human T-lymphotropic virus (HTLV) Infection in People Living With HIV/AIDS in the Pará State, Amazon Region of Brazil. Front Microbiol, 2020; 11:572381.
55.
Caterino-de-AraujoA, CamposKR, PetrucciTVB, et al.Surveillance of human retroviruses in blood samples from patients with hepatitis B and C in São Paulo, Brazil. Rev Soc Bras Med Trop, 2020; 53:e20190378.
56.
de Fátima Castro MendesM, de Ribamar Oliveira LimaJ, de Oliveira de MeloB, et al.Molecular detection of human T cell lymphotropic virus type 1 in pregnant women from Maranhão state, Brazil. Braz J Microbiol, 2020; 51(2):637–645.
57.
SouzaRL de, PereiraMVS, SilvaRM da, et al.Molecular epidemiology of HIV-1 and HTLV-1/2 among female sex workers in four cities in the state of para, Northern Brazil. Front Microbiol [Internet]. 2020 [cited 2022 Mar 15];0; doi: 10.3389/fmicb.2020.602664
58.
BandeiraLM, Motta-CastroAR, PugaM, et al.Human T-cell leukemia virus type 1 infection among Japanese immigrants and their descendants living in Southeast Brazil: A call for preventive and control responses [Internet]. J Brasil Doenças Sex Trans, 2021; doi: 10.5327/dst-2177-8264-202133p012
59.
Maneschy C deA, de Alcântara ManeschyC, BarileKA, et al.Epidemiological and molecular profile of blood donors infected with HTLV-1/2 in the State of Pará, Northern Brazil [Internet]. Braz J Microbiol, 2021; 52(4):2001–2006; doi: 10.21203/rs.3.rs-155429/v1
60.
OrlettiMPS, AssoneT, SarnagliaGD, et al.Prevalence of infection by human T Cell lymphotropic viruses (HTLV-1/2) in adult population in Vitória-ES. Braz J Infect Dis, 2021; 25(5):101631.
61.
Santos de SouzaM, Prado GonçalesJ, Santos deMoraisVM, et al.Prevalence and risk factor analysis for HIV/HTLV 1/2 coinfection in Paraíba state, Brazil. J Infect Dev Ctries, 2021; 15(10):1551–1554.
62.
MeloB and eiraL, Moreira PugaMA, CrodaJ, et al.Human T-lymphotropic virus-1/2 infection in Central Brazil prisons: A multicenter study. Front Microbiol, 2021; 12:740245.
63.
LiaoQ, ShanZ, WangM, et al.Prevalence and evolutionary analyses of human T-cell lymphotropic virus in Guangdong province, China: Transcontinental and Japanese subtype lineages dominate the prevalence. PLoS Negl Trop Dis, 2021; 15(2):e0009043.
64.
ChangL, OuS, ShanZ, et al.Seroprevalence of human T-lymphotropic virus infection among blood donors in China: A first nationwide survey. Retrovirology, 2021; 18(1):2.
65.
TrujilloJM, ConchaM, MuñozA, et al.Seroprevalence and cofactors of HTLV-I infection in Tumaco, Colombia. AIDS Res Hum Retroviruses, 1992; 8(5):651–657.
66.
ArangoC, MaloneyE, RugelesMT, et al.HTLV-I and HTLV-II coexist among the Embera and Inga Amerindians of Colombia [Internet]. J Acquir Immune Defic Syndr Hum Retrovirol, 1999; 20:102–103; doi: 10.1097/00042560-199901010-00021
67.
MuñozM, CarvalhoS, DonadoJH, et al.SHTLV-I/II seroprevalence in blood donors of Hospital Pablo Tobón Uribe Blood Bank during the period 2014-2015. Biomédica, 2018; 38(1):37–41.
68.
Cardona-AriasJA, Vélez-QuinteroC, Calle-GonzálezOV, et al.Seroprevalence of human T-lymphotropic virus HTLV and its associated factors in donors of a blood bank of Medellín-Colombia, 2014-2018 [Internet]. PLoS One, 2019; 14:e0221060; doi: 10.1371/journal.pone.0221060
69.
MachucaA, TusetC, SorianoV, et al.Prevalence of HTLV infection in pregnant women in Spain. Sex Transm Infect, 2000; 76(5):366–370.
70.
TreviñoA, AguileraA, CaballeroE, et al.Seroprevalence of HTLV-1/2 infection among native and immigrant pregnant women in Spain [Internet]. AIDS Res Human Retrov, 2009; 25:551–554; doi: 10.1089/aid.2008.0268
71.
TreviñoA, GarcíaJ, de MendozaC, et al.Prevalence of HTLV-1/2 infections in Spain: A cross-sectional hospital-based survey [Internet]. AIDS Res Human Retrov, 2010; 26:861–864; doi: 10.1089/aid.2009.0234
72.
RamosJM, MillaA, TreviñoA, et al.Seroprevalence of HTLV infection among immigrant pregnant women in the Mediterranean coast of Spain. J Clin Virol, 2011; 51(3):192–194.
73.
TreviñoA, BenitoR, CaballeroE, et al.HTLV infection among foreign pregnant women living in Spain. J Clin Virol, 2011; 52(2):119–122.
74.
TreviñoA, AguileraA, CaballeroE, et al.Trends in the prevalence and distribution of HTLV-1 and HTLV-2 infections in Spain. Virol J, 2012; 9:71.
75.
MurphyEL, VarneyKF, MiyasakiNT, et al.Human T-lymphotropic virus type I seroprevalence among Japanese Americans. West J Med, 1993; 158(5):480–483.
76.
ThiedeH, HarrisNV, McGoughJP, et al.Prevalence of HTLV types I and II among drug users in King County, Washington. West J Med, 1994; 160(6):540–544.
77.
RossheimAE-B, CunninghamTD, TroySB. Human T-lymphotropic virus co-infections in adults infected with human immunodeficiency virus. Am J Med Sci, 2016; 352(3):258–260.
78.
Le HesranJY, Le HesranJY, DelaporteE, et al.Demographic factors associated with HTLV-1 infection in a Gabonese community [Internet]. Int J Epidemiol, 1994; 23:812–817; doi: 10.1093/ije/23.4.812
79.
BertheratE, MakuwaM, RenautA, et al.HIV-1, HTLV-I, and HTLV-II in a semiurban population in East Gabon [Internet]. J Acquir Immune Defic Syndr Hum Retrovirol, 1998; 19:430–432; doi: 10.1097/00042560-199812010-00018
80.
CaronM, BessonG, PadillaC, et al.Revisiting human T-cell lymphotropic virus types 1 and 2 infections among rural population in Gabon, central Africa thirty years after the first analysis. PLoS Negl Trop Dis, 2018; 12(10):e0006833.
81.
CarlesG, TortevoyeP, TuppinP, et al.Infection par le rétrovirus HTLV-1 et grossesse [Internet]. J Gynécol Obst Biol Reprod, 2004; 33:14–20; doi: 10.1016/s0368-2315(04)96307-7
82.
JeannelD, KouroumaK, FretzC, et al.Regional differences in human retroviral infections HIV-1, HIV-2, and HTLV-I/II in Rural Guinea (West Africa) [Internet]. J Acquir Immune Defic Syndr Hum Retrovirol, 1995; 8:315–318; doi: 10.1097/00042560-199503010-00016
83.
ZaaijerHL, Dudok de WitC, CuypersHT, et al.[Prevalence of human T-cell lymphotropic virus type I among Dutch blood donors]. Ned Tijdschr Geneeskd, 1993; 137(49):2541–2543.
84.
RoyM, DasMK, IshidaT, et al.Absence of HTLV-I infection in some Indian populations. Indian J Med Res, 1994; 100:160–162.
85.
RafatpanahH, Hedayati-MoghaddamMR, FathimoghadamF, et al.High prevalence of HTLV-I infection in Mashhad, Northeast Iran: A population-based seroepidemiology survey. J Clin Virol, 2011; 52(3):172–176.
86.
AzarpazhoohMR, HasanpourK, GhanbariM, et al.Human T-lymphotropic virus type 1 prevalence in northeastern Iran, Sabzevar: An epidemiologic-based study and phylogenetic analysis. AIDS Res Hum Retroviruses, 2012; 28(9):1095–1101.
87.
GhaffariJ, EbrahimiM, MakhloughA, et al.Seroepidemiology of human T-cell lymphotropic virus 1 infection in hemodialysis patients: Should we be concerned about it?. Iran J Kidney Dis, 2013; 7(3):187–190.
88.
KalaviK, MoradiA, TabarraeiA. Population-based seroprevalence of HTLV-I infection in Golestan Province, Southeast of Caspian Sea, Iran. Iran J Basic Med Sci, 2013; 16(3):225–228.
89.
SafabakhshH, JalalianM, KarimiG. Seroepidemiology of human T-cell lymphotropic virus type-1 (HTLV1) in Mashhad. Glob J Health Sci, 2014; 6(5):99–104.
90.
RafatpanahH, TorkamaniM, ValizadehN, et al.Prevalence and phylogenetic analysis of HTLV-1 in a segregated population in Iran [Internet]. J Med Virol, 2016; 88:1247–1253; doi: 10.1002/jmv.24448
91.
SaghafiM, RezaieyazdiZ, NabaviS, et al.HTLV-1 seroprevalance in sarcoidosis. A clinical and laboratory study in northeast of Iran. Int J Rheum Dis, 2018; 21(6):1309–1313.
92.
YahyapourY, AghajanipourK, MirSM, et al.Human T- lymphotropic virus type 1 in blood donors from Babol County Blood Transfusion Center: A pilot study from Northern Iran [Internet]. Jundishapur J Microbiol, 2017; 10; doi: 10.5812/jjm.13757
93.
FerdowsiS, NajafzadehM, AmeliMR, et al.Evaluating the frequency of human T-lymphotropic virus type 1 infection in Iranian population. Iranian J Blood Cancer, 2019, 11(2):47–50.
94.
YousefiM, SharifzadehGR, EbrahimzadehA, et al.Prevalence and associated risk factors of HTLV-1 and co-infections of blood-borne viruses in Birjand, Iran's Eastern Border. Arch Iran Med, 2020; 23(10):672–677.
95.
Mehrabi HabibabadiH, ParsaniaM, PourfathollahAA, et al.Prevalence and phylogenetic analysis of HTLV-1 in blood donors in Golestan Province, in the Northeast of Iran. J Virol Methods, 2021; 290:114073.
96.
SuligoiB, GalliC, CiutaS, et al.Low seroprevalence of HTLV-I and HTLV-II in patients with a sexually transmitted disease. Study Group for HTLV and STDs. Eur J Epidemiol, 1999; 15(3):225–229.
97.
MuneishiH, TaguchiH, SawadaT, et al.Prevalence of HTLV-I in leprosy patients in two sanatoriums in Japan. J Acquir Immune Defic Syndr Hum Retrovirol, 1998; 17(4):380–383.
98.
YamadaT, TogashiT, TsutsumiH, et al.Prevalence of human T-lymphotropic virus type 1 carriers among pregnant women in Hokkaido, Japan. Microbiol Immunol, 2014; 58(8):427–431.
99.
SagaraY, IwanagaM, MoritaM, et al.Fine-scale geographic clustering pattern of human T-cell leukemia virus type 1 infection among blood donors in Kyushu-Okinawa, Japan. J Med Virol, 2018; 90(10):1658–1665.
100.
DiarraAB, KouribaB, GuindoA, et al.Prevalence of HTLV-I virus in blood donors and transfusion in Mali: Implications for blood safety. Transfus Clin Biol, 2014; 21(3):139–142.
101.
ManhiçaI, BhattN, IsmaelN, et al.First report of prevalence of HTLV-1 among HIV-1/2-infected children in Mozambique. J Acquir Immune Defic Syndr, 2017; 74(2):e54–e56.
102.
BatsuuriJ, DashnyamB, MaidarJ, et al.Absence of human T-lymphotropic retrovirus type-1 (HTLV-1) in different populations of Mongolia. Scand J Infect Dis, 1993; 25(3):398–399.
103.
DurojaiyeI, AkinbamiA, DosunmuA, et al.Seroprevalence of human T lymphotropic virus antibodies among healthy blood donors at a tertiary centre in Lagos, Nigeria. Pan Afr Med J, 2014; 17:301.
104.
SandersRC, Wai'inPM, AlexanderSS, et al.The prevalence of antibodies to human T-lymphotropic virus type I in different population groups in Papua New Guinea. Arch Virol, 1993; 130(3-4):327–334.
105.
TakaoS, IshidaT, BhatiaKK, et al.Seroprevalence of human T-lymphotropic virus type 1 in Papua New Guinea and Irian Jaya measured using different western blot criteria. J Clin Virol, 2000; 16(2):129–133.
106.
GotuzzoE, SánchezJ, EscamillaJ, et al.Human T cell lymphotropic virus type I infection among female sex workers in Peru. J Infect Dis, 1994; 169(4):754–759.
107.
AlarcónJO, FriedmanHB, MontanoSM, et al.High endemicity of human T-cell lymphotropic virus type 1 among pregnant women in Peru. J Acquir Immune Defic Syndr, 2006; 42(5):604–609.
108.
BlasMM, AlvaIE, GarcíaPJ, et al.High prevalence of human T-lymphotropic virus infection in indigenous women from the Peruvian Amazon. PLoS One, 2013; 8(9):e73978.
109.
ItaF, MayerEF, VerdonckK, et al.Human T-lymphotropic virus type 1 infection is frequent in rural communities of the southern Andes of Peru. Int J Infect Dis, 2014; 19:46–52.
110.
AdesAE, ParkerS, WalkerJ, et al.Human T cell leukaemia/lymphoma virus infection in pregnant women in the United Kingdom: Population study. BMJ, 2000; 320(7248):1497–1501.
111.
AnderssonS, KrookA, KällK, et al.HTLV infections among Swedish intravenous drug users in 1992. Scand J Infect Dis, 1995; 27(6):547–550.
112.
BöniJ, BissetLR, BurckhardtJJ, et al.Prevalence of human T-cell leukemia virus types I and II in Switzerland. J Med Virol, 2004; 72(2):328–337.
113.
AlbergaH, GoubauP, DesmyterJ, et al.[Prevalence of human T-lymphotropic virus, Type 1 and 2 in blood donors and patients with sexually transmissible diseases in Surinam]. Ned Tijdschr Geneeskd, 1996; 140(33):1689–1692.
114.
ChenCJ, HsiehSF, YangCS. Seroepidemiology of human T-lymphotropic virus type I infection among intravenous drug abusers in Taiwan. J Med Virol, 1994; 42(3):264–267.
115.
Website [Internet]. Available from: https://hdr.undp.org/en/content/human-development-report-2020-readers-guide
116.
DuarteGR. Guiana Francesa: Uma análise geohistórica. Confins, 28 | 2016 Número 28 [Internet]. 2016 Sep 22 [cited 2021 Aug 31];(28). Available from: http://journals.openedition.org/confins/11072
117.
World Population Prospects—Population Division—United Nations [Internet]. [cited 2021 Oct 22]. Available from: https://population.un.org/wpp/DataQuery/
118.
Lista de países por população [Internet]. [cited 2022 Feb 21]. Available from: https://pt.wikipedia.org/w/index.php?title=Lista_de_pa%C3%ADses_por_popula%C3%A7%C3%A3o&oldid=62848422
119.
Estimates and Projections, Aboriginal and Torres Strait Islander Australians [Internet]. Australian Bureau of Statistics. 2019 [cited 2022 Apr 18]. Available from: https://www.abs.gov.au/statistics/people/aboriginal-and-torres-strait-islander-peoples/estimates-and-projections-aboriginal-and-torres-strait-islander-australians/latest-release
120.
Website [Internet]. Available from: https://doi.org/10.1111/bjh.15160
121.
[No title] [Internet]. [cited 2021 Nov 2]. Available from: https://www.mhlw.go.jp/bunya/kodomo/boshi-hoken16/dl/06.pdf
122.
AtsmaF, de VegtF. The healthy donor effect: A matter of selection bias and confounding. Transfusion, 2011; 51(9):1883–1885.
123.
Brasil. Ministério da Saúde. Portaria n° 1.376, de 19 de novembro de 1993. [Internet] 1993. [cited19set.2022]. Available from: http://redsang.ial.sp.gov.br/site/docs_leis/ps/ps29.pdf
124.
MachadoCV, de Faria BaptistaTW, de LimaLD. Políticas de saúde no Brasil: Continuidades e mudanças. Resenhas: BOOK REVIEWS • Cad. Saúde Pública 29(9) • Set 2013 • https://doi.org/10.1590/0102-311XRE020913
125.
RodriguesCL, ZiegelmannPK. Metanálise: Meta-analysis: a practical guide [Internet] 2010;30(4). Available from: https://seer.ufrgs.br/hcpa/article/view/16571
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
